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Ultrastructural damageLate-onset dementia is a major health concern in the ageing population. Alzheimer's disease (AD) accounts for
the largest proportion (65–70%) of dementia cases in the older population.
Despite considerable research effort, the pathogenesis of late-onset AD remains unclear. Substantial evidence
suggests that the neurodegenerative process is initiated by chronic cerebral hypoperfusion (CCH) caused by age-
ing and cardiovascular conditions. CCH causes reduced oxygen, glucose and other nutrient supply to the brain,
with direct damage not only to the parenchymal cells, but also to the blood–brain barrier (BBB), a key mediator
of cerebral homeostasis. BBB dysfunctionmediates the indirect neurotoxic effects of CCH by promoting oxidative
stress, inflammation, paracellular permeability, and dysregulation of nitric oxide, a key regulator of regional
blood flow. As such, BBB dysfunction mediates a vicious circle in which cerebral perfusion is reduced further
and the neurodegenerative process is accelerated. Endothelial interaction with pericytes and astrocytes could
also play a role in the process. Reciprocal interactions between vascular dysfunction and neurodegeneration
could further contribute to the development of the disease.
A comprehensive overview of the complex scenario of interacting endothelium-mediated processes is currently
lacking, and could prospectively contribute to the identification of adequate therapeutic interventions.
This study reviews the current literature of in vitro and ex vivo studies on endothelium-mediatedmechanismsun-
derlying vascular dysfunction in AD pathogenesis, with the aim of presenting a comprehensive overview of the
complex network of causative relationships. Particular emphasis is given to vicious circles which can accelerate
the process of neurovascular degeneration.
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Late-onset dementia – an irreversible and debilitating condition
characterised by progressive cognitive decline – is a major health con-
cern in the ageing population. Alzheimer's disease (AD) accounts for
the largest proportion (65–70%) of dementia cases in the older popula-
tion (Plassman et al., 2007;Whitehouse et al., 1997;Wilson et al., 2011).
Despite considerable research effort, the pathogenesis of sporadic AD
remains unclear. A longstanding hypothesis proposed by Hardy and
Higgins (1992) – known as the “amyloid cascade hypothesis” – suggests
that AD pathology is initiated by the deposition of insoluble amyloid β
(Aβ) fragments resulting from amyloid precursor protein (AβPP) prote-
olysis. An imbalance between Aβ production and clearance results in
toxic Aβ concentrations, neuronal tau protein hyperphosphorylation
and consequent neurofibrillary tangle formation (Hardy and Selkoe,
2002). However, substantial evidence (Kelleher and Soiza, 2013; De La
Torre, 2004; Cordonnier and van der Flier, 2011; Zlokovic, 2011; Van
Norden et al., 2012) suggests that the neurodegenerative process is ini-
tiated by chronic cerebral hypoperfusion caused by ageing, vascular
conditions such as hypertension, atherosclerosis, type II diabetes, hy-
percholesterolemia (Kelleher and Soiza, 2013; Cordonnier and van der
Flier, 2011; Zlokovic, 2011; Van Norden et al., 2012; De la Torre,
2012), and possibly cardiac conditions such as atrial fibrillation and
chronic heart failure (De La Torre, 2004; Abete et al., 2014; Kalaria,
2003). Chronic hypoperfusion causes reduced oxygen, glucose and
other nutrient supply to the brain (Farkas et al., 2007), with direct dam-
age not only to the parenchymal cells, but also to the blood–brain barri-
er (BBB), a key mediator of cerebral homeostasis. BBB dysfunction
mediates the indirect neurotoxic effects of chronic hypoperfusion by
promoting oxidative stress (Kelleher and Soiza, 2013; Cai et al., 2011;
Sanchez et al., 2013), inflammation (Grammas, 2011; Tripathy et al.,
2013; Abbott, 2000; Grammas et al., 2006a), impaired glucose transport
across the BBB (Yamagata et al., 2004; Shah et al., 2012; Kalaria andHarik, 1989a), BBB permeability (Yamagata et al., 2004; Krizbai et al.,
2005; Mark and Davis, 2002), and dysregulation of nitric oxide (NO)
(Perry et al., 2000; Austin et al., 2013;Walsh et al., 2009), a keymediator
of vascular tone and regional blood flow regulation (Katusic and Austin,
2014; Toda et al., 2009). As such, BBB dysfunction could mediate a vi-
cious circle in which cerebral perfusion is reduced further and the
neurodegenerative process is accelerated (Nunomura et al., 2006;
Guglielmotto et al., 2009; Coma et al., 2008). Adjacent to endothelial
cells, astrocytes and pericytes could also play a role in this process. In-
deed, astrocytes are known to amplify the endothelial response during
inflammation (Abbott et al., 2006;Minagar et al., 2002), and some stud-
ies suggest that pericytes could contribute tomicrovascular tone regula-
tion and regional blood flow distribution (Peppiatt et al., 2006; Hall
et al., 2014; Winkler et al., 2014). Reciprocal interactions between vas-
cular dysfunction and neurodegeneration have also been proposed
(Burgmans et al., 2013; Iadecola, 2010), supported by a large body of
in vitro evidence of oligomeric Aβ interaction with endothelial (Suo
et al., 1998; Fonseca et al., 2013, 2014; Giri et al., 2002; Grammas
et al., 1995a; Xu et al., 2001) and smooth muscle cells (Ruzali et al.,
2013; Vromman et al., 2013), and by post mortem studies showing
coexisting cerebrovascular disease in most AD patients (Kelleher and
Soiza, 2013; Jellinger and Attems, 2005; De la Torre, 2002; Kalaria,
2000).
Neurofibrillary tangles (NFT), a characteristic hallmark of AD togeth-
erwith senile plaques, have also been proposed to originate from chron-
ic cerebral hypoperfusion (De la Torre and Stefano, 2000), although
manifesting in the later stage of AD progression (Sun and Alkon,
2004). However, there is limited quantitative evidence of a direct link
between microvascular dysfunction and NFT formation, and microvas-
cular abnormalities appear to correlate to Aβ deposition rather than to
neurofibrillary tangles (Kalaria, 1997; Jeynes and Provias, 2008).
As early elements which could precede the clinical manifestation of
AD by years or even decades (Alonso et al., 2009; Braak et al., 1999;
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and BBBdysfunction emerge as a crucial topic of investigation,with pro-
spective potential for therapeutic intervention.
1.1. Review focus
The endothelium-mediated processes implicated in the vascular
component of AD pathogenesis interact in a complex network of
cause–effect relationships. A comprehensive overview of this network
is currently lacking, and could prospectively contribute to the identifica-
tion of adequate therapeutic interventions.
This study reviews the current literature of in vitro and ex vivo
studies on endothelium-mediated mechanisms underlying vascular
dysfunction in AD pathogenesis (Sections 2–4),with the aim of present-
ing a comprehensive overview of the network of causative relationships
(Section 5). Particular emphasis is given to mediators of detrimental vi-
cious circles, such as hypoxia/ischemia, oxidative stress, inflammation
and mitochondrial dysfunction. The potential role of pericytes and as-
trocytes in this complex scenario is also investigated.
2. BBB dysfunction in AD
In the cerebral circulation, the BBB is a highly specialized structure
whichmaintains neuronal homeostasis by regulating theflux of electro-
lytes, metabolites, toxicmolecules, xenobiotics, and circulating immune
cells between the bloodstream and the brain parenchyma (Abbott et al.,
2010; Bradbury, 1993). The BBB is formed by the capillary endothelium,
the basement membrane, and the surrounding pericytes and astrocyte
end-feet. The endothelial cells of the BBB adhere to one another through
junctional structures, termed tight (TJ) and adherens junctions, which
regulate paracellular permeability (the so-called ‘gate function’), and
maintain the polarity of enzymes and receptors on the luminal and
abluminal domains of the endothelial membrane (‘fence function’)
(Abbott et al., 2006; Deli et al., 2005). Small lipid-soluble molecules,
such as oxygen, carbon-dioxide, and typical therapeutic drugs, can dif-
fuse freely across the BBB (Zlokovic, 2008), whereas the exchange of
larger molecules occurs by active transport (transcytosis) through the
cell body or byparacellular transport (Zlokovic, 2011; Lyros et al., 2014).
In AD, the BBB undergoes functional and structural changes which
disrupt the gate function, impair energy supply to the brain, reduce
the clearance of Aβ, and produce neurotoxic molecules. Due to its cen-
tral role in cerebral homeostasis, the BBB becomes both a target and
source of injury in the development of the disease.
2.1. Impaired glucose transport
Glucose – the main energy source for the brain – requires a carrier
(transporter) to cross the BBB. In the human BBB, this is mainly
achieved by glucose transporter 1 (GLUT-1).
Glucose uptake in the brain is determined by the concentration of
glucose in the plasma, aswell as the concentration of GLUT transporters
in the BBB. Positron emission tomography (PET) studies have demon-
strated reduced regional metabolic rate in the AD brain, especially in
temporal and parietal cortical regions (Benson et al., 1983; Duara
et al., 1986; Faulstich, 1991; Heiss et al., 1991). Impaired glucose trans-
port across the BBB could contribute to this condition by acting as rate
limiting factor (Shah et al., 2012), as suggested by autopsy studies
showing reduced concentration of GLUT transporters in the microvas-
culature of the AD brain (Kalaria and Harik, 1989a; Simpson et al.,
1994; Harik, 1992).
Among possible causes of impaired glucose transport, it has been
proposed that mitochondrial dysfunction in the BBB endothelium
could play an important role (Shah et al., 2012; Cunnane et al., 2011).
In addition, the ultrastructural alterations observed in capillary walls
of the AD brain (Aliev et al., 2002a; Claudio, 1996; Stewart et al.,
1992) might – in principle – induce structural alterations of transportproteins (Farkas and Luiten, 2001), thus hindering the active transport
of nutrients across the BBB. However, it is also possible that this putative
transport defect does not lower intra-cerebral glucose content to a suf-
ficient extent to alter the metabolic rate (Jagust et al., 1991; Friedland
et al., 1989). Furthermore, it remains unclear whether the hypothesised
rate limiting effect of impaired transport could explain the early mani-
festation of hypometabolism observed in AD (Foster et al., 1984).
Taken together, the available evidence suggests, but does not prove,
that impaired GLUT-dependent transport could contribute to the re-
duced glucose metabolism observed in AD, and this contribution could
be aggravated bymitochondrial dysfunction and ultrastructural cellular
damage.
2.2. Oxidative stress
At low concentrations, reactive oxygen species (ROS) participate in
the regulation of cell functioning by activating intracellular signalling
cascades, whereas at higher concentrations ROS may cause oxidative
stress, a condition in which the production of ROS overcomes antioxi-
dant defences (Wang et al., 2006a), resulting in damage to lipids, pro-
teins, and DNA (Valko et al., 2007).
Oxidative stress is a feature of ageing (Bennett et al., 2009; Harper
et al., 2004), and age-related diseases (Aliev et al., 2002b), including
AD (Perry et al., 2000; Smith et al., 1996, 1997). Due to its high rate of
oxygen consumption, presence of redox-active metals and limited anti-
oxidant enzymatic defences, the brain is particularly vulnerable to oxi-
dative damage (Valko et al., 2007; Aliev et al., 2011), and increased
levels of lipid peroxidation and nucleic acid oxidation are a consistent
finding in the AD brain (Aliev et al., 2002a; Smith et al., 2000).
Because Aβ plaques sequester redox-activemetals (Nunomura et al.,
2006), and Aβ deposits have been found in perivascular cells and
perivascular spaces surrounding cortical microvessels (Aliev et al.,
2002a), it has been suggested that the cerebral microvasculature, and
in particular the BBB, could actively contribute to the oxidative injury
observed in the AD brain. This view is supported by the highly reactive
nature of the BBB endothelium, which is both a source of, and a target
for, ROS and inflammatory proteins (Tripathy et al., 2013; Grammas
et al., 2011a); and by the peculiar features of the ultrastructural damage
in endothelial and perivascular cells, which is characterised by large
lipid-laden vacuoles and damaged, swollen mitochondria (Aliev et al.,
2002a). Although a causative link between oxidative stress and micro-
vascular damage has not been established in the AD brain in vivo,
in vitro studies have shown that chronic oxidative stress increases BBB
permeability, promotes leukocyte adhesion, and alters endothelial sig-
nal transduction and redox-regulated transcription factors (Aliyev
et al., 2005).
Taken together, these data suggest that the dysfunctional BBB could
actively foster the neurodegenerative process through separate (and
possibly synergistic) pathways, by increasing the levels of ROS in the
brain, by promoting the extravasation of monocytes and toxic mole-
cules into the perivascular space, and by further reducing regional per-
fusion in a vicious circle.
2.3. NO-mediated disruption of microvascular homeostasis
NO is an important regulatory molecule with a fundamental role in
neurovascular homeostasis. In endothelial cells, NO regulates vascular
tone, platelet aggregation, leukocyte adhesion, and endothelial junc-
tional permeability (Maxwell, 2002; Moncada and Higgs, 1993;
Schini-Kerth, 1999). NO is produced by three isoforms of NO synthase
(NOS), endothelial (eNOS), neuronal, and inducible (iNOS). The latter
is induced (also in endothelial cells) by transcription factors which are
activated by cytokines during inflammation (Morris and Billiar, 1994),
and is capable of increasing overall NO production, far beyond the levels
produced by eNOS (Dorheim et al., 1994).
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crease of baseline endothelial NO synthesis (Austin et al., 2013). Re-
duced endothelial NO production/bioavailability results in impaired
vasodilation, reduced regional cerebral bloodflow (CBF), and accumula-
tion of oxidative stress, which are common features in AD (Aliev et al.,
2009). There is evidence that pharmacological or genetic inactivation
of eNOS in cultured brain microvascular endothelial cells increases the
expression of AβPP and β-site AβPP cleaving enzyme 1 (BACE-1), as
well as Aβ production (Austin et al., 2010). Consistentlywith thesefind-
ings, other studies (Provias and Jeynes, 2008; Jeynes and Provias, 2009)
have shown an inverse correlation between eNOS-positive capillaries
and Aβ senile plaques in cortical samples of AD brains.
Chronic inhibition of constitutive NO production also increases en-
dothelial permeability during inflammation (Wong et al., 2004). Expo-
sure of cultured human brain endothelial cells to cytokines (tumour
necrosis factor (TNF)-α, interleukin (IL)-1β, interferon (IFN)-γ), de-
creased transendothelial electrical resistance (TEER) and increased TJ
permeability (Wong et al., 2004), which could be reverted by NO
donors.
Constitutive endothelial NO is reduced in chronic hypoperfusion, as
evidenced by reduced eNOS immunostaining in rat hippocampal capil-
laries following chronic bilateral carotid occlusion (De la Torre and
Aliev, 2005), with concomitant evidence of mitochondrial damage in
endothelial and perivascular cells. These abnormalities were associated
with amyloid deposition surrounding the capillary wall, suggesting a
possible interaction of the vascular damage with Aβ deposits. In addi-
tion, occluded rats (but not controls) showedworsened spatialmemory
following administration of eNOS inhibitors 8 weeks after occlusion.
These findings suggest that vascular NO derived from eNOS may play
an important role in regulating microvascular tone in the attempt to
contrast the chronic reduction of CBF (De la Torre and Aliev, 2005).
Collectively, these data indicate that endothelial NO dysregulation
may contribute to BBB dysfunction and permeability, oxidative stress,
chronic regional hypoperfusion, and increased Aβ production. The ef-
fects of reduced endothelial NO could also be increased during inflam-
mation and chronic hypoperfusion in a detrimental vicious circle,
which could accelerate the neurodegenerative process in AD.
2.4. Aβ–endothelium interaction
2.4.1. Aβ trafficking and impaired Aβ clearance
Aβ clearance from the brain is mediated by various mechanisms,
such as glial phagocytosis, enzymatic degradation, transport to the cere-
brospinal fluid with subsequent re-absorption into the venous circula-
tion, and direct transport across the BBB (Zlokovic, 2004).
As macromolecules, Aβ peptides cross the BBB by active transport.
The receptor for advanced glycation end-products (RAGE) mediates
Aβ transcytosis to the perivascular space (Aβ influx) (Deane et al.,
2003; Mackic et al., 1998), whereas Aβ efflux is mediated by multiple
receptors, and in particular the lipoprotein receptor-related protein 1
(LRP-1) (Burgmans et al., 2013; Ueno et al., 2010), and ATP binding cas-
sette (ABC) subfamily B member 1, also termed P-glycoprotein (P-gp)
(Cirrito et al., 2005; Silverberg et al., 2010a; Van Assema et al., 2012).
Data from mouse models suggest that RAGE expression increases with
age (Silverberg et al., 2010b), whereas LRP-1 and P-gp decline
(Silverberg et al., 2010a), suggesting a possible path for increased Aβ
deposition, and decreased clearance, respectively. P-gp expression was
also found to inversely correlate with the deposition of Aβ1–40 and
Aβ1–42 in elderly non-demented humans (Vogelgesang et al., 2002), in-
dicating a possible dose-dependent path for Aβ accumulation with in-
creasing age.
Due to the potential implication of impaired Aβ transport across the
BBB on the development of AD, this topic has attracted substantial re-
search effort. While some biopsy studies have shown increased Aβ in-
flux mediated by RAGE upregulation in the human AD brain (Jeynes
and Provias, 2008; Miller et al., 2008; Donahue et al., 2006), reportsfrom animal studies are conflicting. On the other hand, evidence of im-
pairedAβ efflux appears to bemore consistent, with an implication of P-
gp and LRP-1 transporters (Burgmans et al., 2013).
Using PET imaging, P-gp function has been found to be reduced in
AD patients (Van Assema et al., 2012), concomitant with increased Aβ
deposition. This finding is consistent with a later in vitro study (Park
et al., 2014), in which Aβ1–42 reduced P-gp expression in a murine
BBB model. Interestingly, the Aβ-induced decrease of P-gp was attenu-
ated when astrocytes were in close contact with endothelial cells, sug-
gesting a protective role for astrocytes in preserving the expression of
this transporter. As biopsy studies show morphological alterations
of endothelial cells, the question arises whether these changes could
“detach” astrocytes from the basement membrane of the BBB endothe-
lium, creating a favourable condition for the inhibition of Aβ efflux
transporters. This hypothesis appears to be supported by the observa-
tion that the above morphological alterations precede the formation of
perivascular Aβ deposits (Aliev et al., 2003). Consistent with Park et al.
(2014), another recent postmortem study (Provias and Jeynes, 2014) re-
ported an inverse correlation between the burden of Aβ senile plaques
and P-gp positive capillaries.
Biopsy studies also suggest that Aβ alters LRP-1 activity (Jeynes and
Provias, 2008; Donahue et al., 2006; Owen et al., 2010). Owen et al.
(2010) proposed that Aβ could impair its own efflux from the brain by
oxidising LRP-1, thereby progressively inhibiting its vascular clearance
pathway. A different view was presented by Wilhelmus et al. (2007)
who found that Aβ increased LRP-1 expression, and proposed that
LRP-1 uptake of Aβ could ultimately saturate, resulting in Aβ accumula-
tion. There is also evidence that BBB-mediated clearance of Aβ could be
modulated by ApoE, in an isoform-dependent manner. Data from
mouse models suggest that ApoE (especially ApoE-ε4) could divert Aβ
efflux to slower receptors than LRP – such as the very low density lipo-
protein receptor – ultimately resulting in Aβ accumulation (Deane et al.,
2008).
Taken together, the above data indicate a possible pathway of BBB-
mediated Aβ accumulation, predominantly based on reduced efflux
rather than increased influx across the barrier. However, the increase
of influx transporters or decrease of efflux transporters only suggests a
possible pathway of Aβ accumulation, it does not prove that the paren-
chymal accumulation of the peptide actually occurs because of this
pathway (Burgmans et al., 2013), especially in vivo. Furthermore, it
has recently been estimated that in the human brain, Aβ efflux across
the BBB accounts for approximately 25% of the overall clearance of Aβ
(Roberts et al., 2014), whereas other pathways – including glial phago-
cytosis, proteolytic degradation, and transport to the cerebrospinal fluid
with subsequent re-absorption into the venous blood (Zlokovic, 2004;
Wang et al., 2006b) – cumulatively account for the predominant pro-
portion, suggesting that impaired BBB-mediated efflux might contrib-
ute to Aβ accumulation only marginally.2.4.2. Endothelium-mediated mechanisms of Aβ production
It has been suggested that AβPP and Aβ observed in the perivascular
space of the AD brain may be of endothelial origin (Bulbarelli et al.,
2012; Kalaria et al., 1996). According to this hypothesis, altered expres-
sion of AβPP in endothelial cells could contribute to the accumulation of
Aβ. Evidence from cultured endothelial cells suggests that thrombin
could be implicated in this process by inducing AβPP secretion through
both intracellular and cell surface pathways (Ciallella et al., 1999).
Prolonged endoplasmic reticulum(ER) stress could also induce intracel-
lular AβPP accumulation and processing, leading to increased intracel-
lular Aβ levels (Plácido et al., 2014).
The possible effects of other stressors such as hypoxia, decreased
glucose supply, and exposure to growth factors, on endothelial Aβ pro-
duction have also been studied. Oxygen–glucose deprivation – an ac-
cepted model of ischemia (Farkas et al., 2007; Brouns and De Deyn,
2009) – has recently been shown to increase Aβ1–42 production in the
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diated by hypoxia inducible factor 1α (HIF-1α) (Bulbarelli et al., 2012).
It has been suggested that endothelial cells in the BBB could also con-
tribute to Aβ production through the activity of enzymes which would
cleave AβPP retained by circulating platelets (whose number is in-
creased in AD), leading to the formation of Aβ fragments (Burgmans
et al., 2013). This hypothesis, however, appears to be supported by lim-
ited experimental evidence.
Collectively, these data suggest a potential active role of the BBB en-
dothelium in the production of Aβ through proteolytic processing of
AβPP. However, the extent to which this phenomenon could contribute
to theparenchymal accumulation of thepeptide and to the neurodegen-
erative process remains to be established in vivo.
2.4.3. Aβ-induced BBB permeability and transmigration of mononuclear
cells
Exposure of endothelial cells to Aβ induces morphological and
biochemical alterations which affect BBB permeability. Deli et al.
(2010) reported Aβ1–42-induced ultrastructural changes in cultured
rat brain endothelial cells such as vacuolization, decreased number of
caveolae and Golgi bodies, and shrunken mitochondria. Irregular
interendothelial junctions with fewer points of contact were also ob-
served, with decreased TEER and increased paracellular permeability
to fluorescein and albumin. TJ integrity in mouse endothelial cells was
also regulated by ApoE (Nishitsuji et al., 2011), and Aβ1–42-RAGE inter-
action (Kook et al., 2012, 2013). Some line of evidence also suggests that
Aβ-induced BBB permeability might be mediated by protein kinase C
(PKC), a family of enzymes involved in transmembrane signal transduc-
tion. PKC participates in the regulation of ion andwater transport in the
brain by stimulating the (Na+/K+)-ATPase pump (Johshita et al., 1993),
and has been indicated as potential mediator of BBB permeability
(Grammas et al., 1995a). Alterations in this enzyme have been reported
in ageing and dementia (Lucke-Wold et al., 2015). In AD, the activity of
PKC and its isoforms is reduced in the cortex and hippocampus (Cole
et al., 1988; Masliah et al., 1991; Wang et al., 1994; Matsushima et al.,
1996), and also in cerebral microvessels (Grammas et al., 1995a;
Moore et al., 1998). Endothelial cells exposed to Aβ1–40, have shown
PKC translocation from the plasma membrane to the intracellular do-
main (inactive state), suggesting that Aβ–endothelium interaction
might contribute to PKC inactivation (Pakaski et al., 2002) and, ulti-
mately, BBB permeability.
Aβ interactionwith endothelial cells has also been shown to increase
adherence and transmigration of monocytes across the BBB (Giri et al.,
2000, 2002; Gonzalez-Velasquez and Moss, 2008). Transmigrated
monocytes can then undergo differentiation into microglia (Eglitis and
Mezey, 1997), and become activated in inflammatory conditions.
In vitro studies have identified potential mechanisms by which Aβ
could promote endothelial adhesion and transmigration of monocytes.
Using a BBB model of human brain microvascular endothelial cells,
Giri et al. (2000) found Aβ1–40-induced monocyte transmigration to
be inhibited by RAGE and platelet endothelial cell adhesion molecule
(PECAM-1) antibodies, which suggests a mediating role of the Aβ influx
transporter. A subsequent study from the same group (Giri et al., 2002)
showed increased transmigration when the apical surface (luminal
side) of the endotheliumwas exposed to Aβ1–40, suggesting that cell po-
larity is another important factor.
Aβ aggregation state has also been shown to play a role. Isolated sol-
uble Aβ aggregates activated adhesion and transmigration of mono-
cytes, whereas un-aggregated monomers and mature fibrils did not
(Gonzalez-Velasquez and Moss, 2008). A further study from the
same group also demonstrated an implication of the nuclear factor-kB
(NF-kB) in mediating Aβ-induced endothelial permeability to mono-
cytes (Gonzalez-Velasquez et al., 2011). Aβ-induced BBB permeability
to mononuclear cells has also been demonstrated in vivo. Farkas et al.
(2003) observed T-lymphocyte transmigration across the BBB after ca-
rotid infusion of Aβ25–35 in rats.In the perivascular space, the vasoactive agents and cytokines re-
leased by activatedmicroglia canmodify TJ assembly, further enhancing
BBB permeability (Abbott et al., 2006; Luissint et al., 2012) and the
paracellular route for mononuclear cell extravasation (Abbott et al.,
2010). This condition could trigger an “autotoxic” vicious circle in
which the activation of microglia could cause neuronal damage, leading
to further microglial activation (Latta et al., 2014; McGeer and McGeer,
1998). The latter effect appears to be sensitive to Aβ. Indeed, microglia
exposed to Aβ1–42 show increased expression of cytokines (Lue et al.,
2001), suggesting that Aβ might exacerbate the effects of the vicious
cycle.
In the AD brain, activated microglia have been shown to co-localise
with perivascular deposits of Aβ (Uchihara et al., 1997), suggesting a
possible implication in the neurodegenerative process. While early ac-
cumulation of microglia seems to play a neuroprotective role by pro-
moting Aβ clearance (Bell and Zlokovic, 2009), data from mouse
models suggest that this neuroprotective effect might be unable to
cope with persistent Aβ accumulation, especially in increasing age and
progressing AD pathology (Hickman et al., 2008), thus supporting the
hypothesis that Aβ-induced monocyte transmigration could play a
role in the neurodegenerative process.
Taken together, these data corroborate the hypothesis that activated
microglia could contribute to exacerbating the inflammation-mediated
neurodegenerative process of AD, especially under conditions of chronic
inflammation and Aβ accumulation.
2.4.4. Vasoactive and apoptotic effects of Aβ
Aβ has vasoactive effects on endothelial cells in vitro, which might
contribute to reducing cerebral perfusion in AD. Deane et al. (2003) ob-
served reduced cortical CBF following infusion of Aβ1–40 in the mouse
brain, which they showed to be Aβ-RAGE dependent and mediated by
the upregulation of the vasoconstrictor endothelin-1 (ET-1). This vaso-
active effect of Aβwas later confirmed by Palmer et al. (2013) who re-
ported Aβ1–40- and Aβ1–42-induced increases in ET-1 release in
primary cultures of human brain endothelial cells.
Aβ has also been shown to cause endothelial cell death in vitro
(Fonseca et al., 2013; Xu et al., 2001; Blanc et al., 1997). Exposure of ce-
rebral endothelial cells to elevated (micromolar) doses of Aβ1–40 caused
mitochondrial dysfunction, nuclear and mitochondrial DNA damage,
and cell death (Xu et al., 2001). Consistent with these findings, a later
study by Fonseca and colleagues showed the activation of ER stress-
induced unfolded protein response (UPR) in rat brain endothelial cells
incubated with Aβ1–40. UPR caused Ca2+ leakage from the ER store
into the cytoplasm, and the activation of both mitochondria-
dependent and independent apoptotic pathways (Fonseca et al.,
2013). A further study from the same group showed Aβ1–40-induced in-
creases of nuclear HIF-1α, vascular endothelial growth factor (VEGF)
and GLUT1, which correlated with oxidative stress markers (Fonseca
et al., 2014). Despite the above VEGF upregulation, several studies
have shown the lack of angiogenesis (Grammas et al., 1995b; Folin
et al., 2005; Hayashi et al., 2009), suggesting that in AD, Aβ–endothelial
interaction could alter the ability of vessels to repair and regenerate
after injury.
Aβ has also been shown to dysregulate endothelial NO production
(Gentile et al., 2004; Toda and Okamura, 2012), possibly through the al-
teration of cytosolic Ca2+ homeostasis caused by inositol 1,4,5-triphos-
phate (IP3) receptor leakage in the ER (Gentile et al., 2004). There is also
evidence that the Aβ-induced reduction of NO bioavailability could be
mediated by oxidative stress (Park et al., 2005).
Collectively, the above in vitro evidence suggests that Aβ–endotheli-
um interaction is able to disrupt intracellular Ca2+ homeostasis, with
detrimental effects on NO synthesis, mitochondrial function, and ROS
production, leading to accelerated cell senescence and death. These ef-
fects could in turn be aggravated by a chronic state of hypoperfusion,
such as resulting from sustained ET-1-mediated microvascular
vasoconstriction.
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ischemia
Chronic regional hypoperfusion in the brain has been shown to com-
promise memory processes (Farkas et al., 2007). Substantial evidence
from in vitro and biopsy studies also supports thehypothesis that chron-
ic cerebral hypoperfusion plays an important role in the development of
AD (De La Torre, 2004; Aliev et al., 2002a; Farkas and Luiten, 2001;
Roher et al., 2003, 2011; Kalaria et al., 2012). Hypoperfusion-induced
hypoxia evokes vascular responses, in which endothelial cells in the ce-
rebral microcirculation play a central role. In vitro and biopsy studies
have shown that hypoxia modulates endothelial junctional permeabili-
ty and ROS generation (Itoh et al., 2006; Strasser et al., 1997) and stim-
ulates pro-inflammatory gene expression (Tripathy et al., 2013;
Sanchez et al., 2012).
The transcription factor HIF-1α is a key regulatorymediator of cellu-
lar responses to hypoxia, acting as sensor of low oxygen tension
(Tripathy et al., 2013). HIF-1α is elevated in the cerebral microcircula-
tion of AD patients and AD mouse models (Grammas et al., 2006b,
2011b), and several studies have reported elevated inflammatory pro-
teins in brain endothelial cells exposed to hypoxia (Tripathy et al.,
2013; Grammas et al., 2011b), suggesting a link between hypoxia and
cerebrovascular inflammation. This hypothesis is also supported by
the work of Yamagata et al. (2004) who reported a decrease in TEER
of endothelial cells exposed to hypoxia, which was associated with IL-
1β and NO.
Hypoxia also affects AβPP processing and Aβ production (Peers
et al., 2009), which could further contribute to the development of AD
pathology. Acute hypoxia increased the expression and activity of
BACE-1, resulting in increased Aβ production (Zhang et al., 2007). Con-
sistently with the above, exposure of cultured endothelial cells to ische-
mia stimulated AβPP expression and cleavage into Aβ, resulting in
increased Aβ production (Bennett et al., 2000).
Hypoxia (Yamagata et al., 2004; Mark and Davis, 2002; Fischer
et al., 1999, 2002; Engelhardt et al., 2014) and ischemia (Brown and
Davis, 2005) have been shown to induce BBB permeability by altering
the expression of junctional proteins. Importantly, the combined ef-
fect of hypoxia and aglycemia appears to enhance the increased BBB
permeability produced by hypoxia alone (Abbruscato and Davis,
1999).
Hypoxia is also a potent stimulus for vascular activation and an-
giogenesis. Microvessels isolated from the brain of AD patients ex-
press a large number of angiogenic proteins, including VEGF
(Grammas et al., 2011b), but without evidence of vascular growth
(Bürger et al., 2009). The lack of vascular response could cause a
chronic state of activation of endothelial cells (Grammas et al.,
2011c), resulting in the release of proinflammatory and potentially
neurotoxic products.
Hypoxia might also contribute to the low levels of mesenchyme ho-
meobox 2 (MEOX-2) – a transcription factor which regulates vascular
cell differentiation and remodelling – which have been found in AD
(Sagare et al., 2012). Downregulation of MEOX-2 in the AD brain endo-
thelium has been shown tomediate an aberrant angiogenic response to
VEGF resulting in vascular regression and reduced CBF (Wu et al., 2005).
Low levels of MEOX-2 also promote endothelial LRP degradation (Wu
et al., 2005), thus favouring Aβ accumulation. Because of the anti-
angiogenic effect of Aβ on brain endothelial cells (Grammas et al.,
1995b; Hayashi et al., 2009; Paris et al., 2004), MEOX-2 might mediate
a cooperative effect of hypoxia and Aβ to induce vascular regression, ul-
timately leading to reduced regional CBF.
Taken together, these data indicatemultiple potential neurotoxic ef-
fects of chronic cerebral hypoperfusion,mediated by hypoxia/ischemia-
induced activation of the BBB endothelium, resulting in Aβ production,
expression of inflammatory proteins, BBB permeability, and vascular re-
gression. The combined effects of hypoxia and aglycemia appear to co-
operate in magnifying the endothelial response.2.6. Microvascular endothelium as mediator of inflammatory processes
Due to their critical role as regulators of cerebral homeostasis, per-
turbations of the microvascular endothelium are closely linked to the
pathophysiology of neuroinflammatory and neurodegenerative disease
states, including AD (Andjelkovic and Pachter, 1998; Grammas et al.,
2002, 2004).
Activated microglia and astrocytes are known endogenous sources
of cytokines and chemokines in the AD brain (Grammas and Ovase,
2001). However, increasing evidence shows that cerebral microvessels
are also capable of expressing inflammatory mediators. Endothelial
cells isolated from AD brains have revealed increased expression of
iNOS (Dorheim et al., 1994), and intercellular adhesion molecule-1
(ICAM-1) (Frohman et al., 1991). Non-stimulated AD microvessels re-
lease higher levels of IL-1β, IL-6, TNF-α and transforming growth factor
(TGF)-β compared to non-ADbrains (Grammas andOvase, 2001, 2002).
In addition, cultured endothelial cells exposed to oxidative stress have
been shown to release thrombin (Grammas et al., 2004), a neurotoxic
protease which has been observed in cerebral microvessels (Grammas
et al., 2006a) as well as senile plaques and NFT (Akiyama et al., 1992).
Thrombin, in turn, mediates the endothelial response to hypoxia by up-
regulating HIF-1α, inflammatory proteins (monocyte chemoattractant
protein (MCP)-1, IL-6), matrix metalloproteinase-2, and ROS (Tripathy
et al., 2013). Inflammation and hypoxia have also been shown to coop-
erate in mediating BBB permeability (Yamagata et al., 2004).
Collectively, these data suggest that the cerebral microvasculature
could actively contribute to the inflammatory process observed in AD,
contributing to the release of neurotoxic agents and increasing endothe-
lial permeability. However, whether inflammation contributes to AD
pathogenesis or it is a neurovascular response to the developing neuro-
degenerative process, remains unclear (Kelleher and Soiza, 2013).
2.7. Mitochondrial dysfunction and damage in BBB endothelial cells
The ATP-dependent transport of macromolecules across the BBB re-
quires efficient mitochondrial function for ATP production, which is
reflected by the high number of mitochondria in endothelial cells of
brain capillaries (Zlokovic, 2011; Farkas and Luiten, 2001). However,
data from autopsy studies of AD brains show reduced mitochondrial
density in the endothelium of cerebral capillaries (Claudio, 1996;
Stewart et al., 1992), as well as mitochondrial damage – evidenced by
broken cristae, membrane disruptions, swelling, and mitochondrial
DNA deletions – which co-localised with amyloid depositions and ath-
erosclerotic lesions (Aliev et al., 2002a).
Structural as well as functional mitochondrial alterations may result
from different and possibly interrelated causes, such as ageing, oxida-
tive stress, and Aβ toxicity.
2.7.1. The effect of ageing
Ageing – the main risk factor for sporadic AD (De la Torre, 2002;
García-Escudero et al., 2013) – is a recognized cause of progressive mi-
tochondrial damage (Valko et al., 2007; Perluigi et al., 2014; Müller
et al., 2010). Ageing cells are affected by increasing oxidative stress
and perturbed energy homeostasis (Aliev et al., 2011; Müller et al.,
2010). Mitochondria play a central role in this process as source of cel-
lular energy (through the production of ATP), as major contributors to
ROS production, and regulators of apoptosis (Müller et al., 2010). Alter-
ations of mitochondrial function are generally associated with an im-
paired electron-transport chain (Müller et al., 2010; Benzi et al., 1992;
Atamna and Frey, 2007; Martínez et al., 1994; Parker et al., 1994;
Mutisya et al., 1994; Cardoso et al., 2004). Mutations of mitochondrial
DNA (mtDNA) also accumulate with advancing age, possibly because
of the proximity ofmtDNA to the respiratory chain (themajor site of ox-
idative stress), and a deficient mtDNA repair mechanism (Müller et al.,
2010).
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Chronic hypoperfusion causes glucose and oxygen deprivation.
These conditions in turn lead to increased ROS production through the
disruption of the mitochondrial respiratory chain and subsequent de-
pletion of ATP, elevation of matrix Ca2+ concentration, and release of
cytochrome C (Farkas et al., 2006).
Mitochondria, however, are not only sources of ROS and oxidative
stress, but also a major target of oxidative damage. Lipids and proteins
in the inner mitochondrial membrane are highly susceptible to ROS,
and lipid peroxidation has been observed in oxidative injury (Müller
et al., 2010; Aliev et al., 2014). Damage to the inner membrane proteins
and/or lipids can result inmembrane depolarization and impairedmito-
chondrial function (Harper et al., 2004). In theADbrain, oxidative injury
has been demonstrated in mitochondria of neuronal (Harper et al.,
2004; Müller et al., 2010; Yao et al., 2009), and also in vascular (endo-
thelial) and perivascular cells (Aliev et al., 2002a, 2008; Aliyev et al.,
2005). Cellular energy failure is demonstrated in the AD brain by post
mortem studies showing deterioration of mitochondrial ultrastructure,
formation of non-mature mitochondria (“hypoxic mitochondria”
(Aliev et al., 2002a; Aliyev et al., 2005)) and excessive mtDNA deletions
(Aliev et al., 2002a, 2014).
2.7.3. The effect of Aβ
In addition to age and oxidative stress, structural and functional mi-
tochondrial alterations may result from the interaction with soluble Aβ
peptides (Xu et al., 2001; Suhara et al., 2003; Crouch et al., 2005), pre-
ceding the formation of Aβ plaques (Manczak et al., 2006). Aβ interac-
tion with mitochondria has been shown to inhibit or reduce the
activity of the respiratory chain complex III (Caspersen et al., 2005)
and complex IV (Crouch et al., 2005; Manczak et al., 2006; Caspersen
et al., 2005), cause mtDNA damage (Xu et al., 2001), and activate apo-
ptotic pathways (Fossati et al., 2012). Atamnaand Frey (2007) proposed
a paradigm of Aβ-mediated mitochondrial dysfunction according to
whichAβwould bind to heme and cause the loss of complex IV and sub-
sequent ATP deficit. According to this paradigm, due to its peroxidase
activity the Aβ–heme complex would cause oxidative damage to endo-
thelial cells, contributing to endothelial dysfunction and ultimately BBB
disruption (Atamna and Frey, 2007).
2.7.4. Consequences of deficient ATP production
Mitochondrial dysfunction results in deficient ATP production,
which impairs ATP-dependent transport mechanisms in the plasma
and ER membranes, such as the sodium (Na+/K+-ATPase) and calcium
(Ca2+-ATPase) pumps (Zlokovic, 2011; De Bock et al., 2013), and the
ABC transporters (Zlokovic, 2011). Impaired Na+ and K+ homeostasis
in the perivascular space influences cell membrane depolarization in
neurons, affecting neuronal and synaptic functions (Zlokovic, 2011).
Impaired sodium and calcium pump function results in the dysregu-
lation of intracellular calcium concentration and signalling. This in turn
affects endothelial NO synthase (eNOS) activity (Busse and Mülsch,
1990) and BBB permeability (De Bock et al., 2013). The deficient ATP
production of dysfunctional mitochondria also leads to the dysregula-
tion of ABC transporters, affecting brain supply of glucose and other nu-
trients, as well as Aβ clearance from the perivascular space (Zlokovic,
2011). ATP deficiency also results in the activation of apoptosis
(Müller et al., 2010).
ATP deficiency, however, does not only affect transport (and ion
flux) across the cell and ER membranes. The ATP-sensitive potassium
channels (mitoKATP) expressed in the mitochondrial membrane, are
also affected in dysfunctional mitochondria. In the brain, mitoKATP are
found at much greater concentrations than in cardiac myocytes, sug-
gesting an important role of these channels in cerebral homeostasis
(Farkas et al., 2006). In normal conditions, the opening of mitoKATP
causes a net influx of K+ into the mitochondrial matrix, resulting in
membrane depolarisation (which reduces the driving force for Ca2+-
uptake, thus opposing Ca2+ accumulation (Calderone et al., 2010) andexcessive ROS production (Garlid et al., 2003; Kruman and Mattson,
1999), with acute neuroprotective effect (Kruman and Mattson, 1999;
Liu et al., 2002)) and accelerated electron transfer in the respiratory
chain, resulting in increased ATP production (Farkas et al., 2006). Pre-
serving this mechanism through the administration of diazoxide – a
mitoKATP channel opener – in conditions of chronic hypoperfusion or is-
chemia/reperfusion injury has been shown to protect neural function
(Farkas et al., 2006) and the BBB barrier function (Lenzsér et al., 2005)
in vivo.
Taken together, ATP deficit causes the alteration of many key ele-
ments of cellular homeostasis, resulting in accelerated cell senescence
and death. ATP deficit also impairs Aβ clearance and nutrient supply
to the brain, thereby contributing to neuronal damage and AD progres-
sion. However, themajority of available quantitative data onmitochon-
drial dysfunction/damage relate to neuronal cells, and only relatively
few studies have investigated the phenomenon in vascular cells in rela-
tion to AD.
2.8. Endothelial interaction with pericytes
Adjacent to the basement membrane of BBB endothelial cells are
pericytes, multifunctional cells which contribute to structural stability,
regulation of capillary blood flow, and clearance of toxic byproducts
(Sagare et al., 2013; Dore-Duffy, 2008). Cross-talk signalling pathways
between endothelial cells and pericytes have been identified (Winkler
et al., 2014; Sagare et al., 2013; Bell et al., 2010), which regulate prolif-
eration, migration, and recruitment of pericytes. In light of these find-
ings, it has been hypothesised (Zlokovic, 2008) that the location of
pericytes along themicrovascular tree could be determined functionally
by the cross-talk with the adjacent endothelial cells. This hypothesis is
consistent with recent in vivo observations of adaptive plasticity of the
cerebral microvasculature in the rat brain (Harb et al., 2013).
Pericytes have typical properties of the contractile apparatus and
their cell membrane expresses receptors for multiple vasoactive media-
tors (Winkler et al., 2014; Bandopadhyay et al., 2001; Hirase et al., 2004;
Kamouchi et al., 2004; Oishi et al., 2007). The restingmembrane poten-
tial of pericytes also appears to be regulated by similar mechanisms to
those observed in vascular smooth muscle cells, with Ca2+-activated
potassium channels, L-type voltage-dependent Ca2+ channels,
agonist-activated Ca2+ channels, and capacitative calcium entry
(Kamouchi et al., 2004). Intracellular elevation of Ca2+ – a phenomenon
which in muscle cells precedes contraction – has also been observed in
stimulated pericytes (Hirase et al., 2004; Kamouchi et al., 2004; Oishi
et al., 2007).
At present, evidence of actual contraction is limited, and predomi-
nantly based on in vitro data. However, a recent study by Hall et al.
(2014) demonstrated that capillaries of anaesthetised mouse somato-
sensory cortex dilate in response to neuronal activity, as a result of
pericyte relaxation. Dilation of capillaries was found to precede that of
the feeding arterioles, suggesting an active role of pericytes in the
hyperaemic response. The authors hypothesised that the relaxation of
pericytes could be induced by prostaglandin E2 or a related compound,
also involving NO production to contrast the synthesis of the vasocon-
strictor 20-hydroxyeicosatetraenoic acid. Whether arterioles receive a
signal to dilate from pericytes or from vasoactive messengers, remains
to be elucidated. The study also showed that when exposed to ischemia,
pericytes first caused vasoconstriction of capillaries then died in rigour.
Although this would be expected to cause a long-lasting increase of the
local resistance to flow, the latter was not measured in the above study.
In summary, a potential role of pericytes in the regulation of regional
CBF is starting to emerge, which could shed new light on microvascular
dysregulation in pathological conditions in which chronic hypoperfu-
sion and microvascular structural/functional damage are present. Al-
though a link with AD has not been established (Winkler et al., 2014),
pericyte loss in mice overexpressing AβPP accelerates amyloid
angiopathy, and pericyte deficiency leads to the development of tau
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tential role of these scaffolding cells in AD development.
2.9. Endothelial interaction with astrocytes
Endothelial cells of the BBB are surrounded by perivascular astrocyt-
ic end-feet. In vitro evidence suggests that astrocytes may influence the
BBB phenotype in the endothelium (Reinhardt and Gloor, 1997; Bauer
and Bauer, 2000). Data from cultured cells demonstrate that astrocytes
can modulate TJs (physical barrier) (Abbott et al., 2006; Farkas and
Luiten, 2001; Dehouck et al., 1990; Rubin et al., 1991), the expression
and localization of transendothelial transporters, including P-gp and
GLUT-1 among others (Abbott et al., 2006; Abbott, 2002). Astrocytes
also upregulate the expression of transferrin receptor and transcytotic
mechanisms for low-density lipoproteins (Dehouck et al., 1994), and se-
crete TGF-β, glial-derived neurotrophic factor, basic fibroblast growth
factor, and angiopoetin 1, which have been shown to induce aspects of
the BBB phenotype in endothelial cells (Abbott et al., 2006). Further-
more, among agents modifying endothelial function and BBB perme-
ability, several can be released by astrocytes, such as ET-1, glutamate,
cytokines (IL-1β, IL-6, TNF-α), and macrophage inflammatory proteins
(Abbott, 2002).
While the above data support the hypothesis of an inductive influ-
ence of astrocytes on the endothelial phenotype in the BBB, reciprocal
influences may also exist (Abbott et al., 2006; Mi et al., 2001). The
perivascular end-feet of astrocytes show several specialized features, in-
cluding the water channel aquaporin 4 (AQP4) and the inward rectifier
(Kir4.1) K+ channel, which are involved in ion and volume regulation
(Abbott et al., 2006). AQP4 co-localises with Kir4.1 and is segregated
by agrin (a large proteoglycan in the basal lamina of the BBB endotheli-
um) to the perivascular astrocytic end-feet (Abbott et al., 2006), sug-
gesting that the endothelium may contribute to specializing the
astrocytic phenotype (Abbott et al., 2006).
Collectively, the above evidence suggests a complex interaction be-
tween astrocytes and BBB endothelial cells, with potential implications
in pathological conditions where the homeostatic function of the BBB is
impaired. Indeed, astrocytes contribute to increase BBB permeability
during inflammation by releasing inflammatory cytokines (Abbott
et al., 2006; Minagar et al., 2002), and in vitro astrocytes amplify the en-
dothelial response to ischemia by increasing junctional permeability,
and adhesion molecule expression (Chaitanya et al., 2014). Although
these data suggest a possible implication of astrocyte–endothelium in-
teraction in AD pathogenesis, this link has not been established.
3. Microvascular innervation in the AD brain
3.1. Intrinsic microvascular innervation and CBF regulation
Cholinergic neurons of the basal forebrain and medial septum pro-
vide the major source of cholinergic intrinsic innervation to the cortex
and hippocampus (Niewiadomska et al., 2011; Sato and Sato, 1995).
The cholinergic cortical vasodilatation induced by stimulation of the
basal forebrain is mediated by NO production, which is thought to re-
flect the activation of nitrergic interneurons and perivascular acetylcho-
line release (Van Beek and Claassen, 2011). Dysfunction of basal
forebrain cholinergic neurons is a characteristic feature of AD (Farkas
and Luiten, 2001; Van Beek and Claassen, 2011),which results in dener-
vation of cortical microvessels (Hamel, 2004; Tong and Hamel, 1999),
reduced expression of eNOS (Rosengarten et al., 2006), and reduced
amount of nitrergic interneurons (Tong and Hamel, 1999). This condi-
tion likely compromises the ability of cortical perfusion to adapt to the
increased metabolic demand caused by neuronal activation (Hamel,
2004; Tong and Hamel, 1999), resulting in depressed CBF regulation,
and ultimately, cerebral hypoperfusion. Experimental evidence sup-
ports the hypothesis that the basal forebrain can participate in neocor-
tical CBF regulation, as it has been shown that unilateral lesions of thebasal forebrain are followed by reduced ipsilateral CBF (Farkas and
Luiten, 2001).
Taken together, the above data suggest that the loss of cortical cho-
linergic innervation might play a role in the regional CBF reduction
observed in AD. However, it is unclear whether this phenomenon
would contribute to the neurodegenerative process from an early
stage (promoting a vicious circle), or only becomemanifest at advanced
stages.
3.2. Microvascular adrenergic innervation and BBB permeability
Adrenergic receptors exist in brain microvessels, with a predomi-
nance of β receptors (Ferrari-DiLeo and Potter, 1985; Harik et al.,
1981; Kalaria et al., 1989; Kobayashi et al., 1982; Peroutka et al., 1980;
Kalaria and Harik, 1989b). Increased levels of β2 and α2 adrenoceptors
have been reported in AD (Kalaria and Harik, 1989b), suggesting possi-
ble alterations of the extrinsic regulation of the microvascular tone,
which might contribute to impairing regional CBF distribution. Because
microvascular noradrenergic innervation in cerebral microvessels also
participates in the regulation of the (Na+/K+)-pump (Harik, 1986)
(an important feature of the BBB function which regulates water and
electrolyte homeostasis) it could be hypothesised that alteration of nor-
adrenergic innervation could also alter fluid exchange at the BBB, thus
creating another potential pathway of impaired CBF distribution. How-
ever, quantitative evidence is needed to confront this hypothesis.
4. Microvascular ultrastructural alterations in the AD brain
Substantial evidence from post mortem biopsy studies shows ultra-
structural alterations in cerebral microvessels of the cortex of the AD
brain (Stewart et al., 1992; Farkas and Luiten, 2001; Kalaria and Pax,
1995; Kalaria and Hedera, 1995), which appear to co-localise with re-
gions of Aβ deposits (Aliev et al., 2002a). Kalaria and Hedera (1995)
found capillaries with collapsed or degenerated endothelium in AD,
which were almost absent in brain regions free of Aβ deposits and in
control subjects. Another study from the same group (Kalaria and Pax,
1995) reported an increased content of collagen IV – themain constitu-
ent of the basement membrane – in microvessels of AD brains com-
pared to age-matched controls. This finding is consistent with the
work of Farkas et al. (2000) who observed a thickened basementmem-
brane and collagen accumulation in cortical microvessels of AD brains.
Similar findings were described by Claudio (1996), who additionally re-
ported an inverse correlation between endothelial pinocytotic vesicle
concentration and mitochondrial concentration. Evidence of increased
size/concentration of endothelial vesicles in AD has also been reported
in other studies (Aliev et al., 2002a; Farkas and Luiten, 2001). Consistent
with Claudio (1996), Stewart and colleagues observed a reduced densi-
ty of mitochondria in the cerebral capillary endothelium of AD patients
(Stewart et al., 1992). The study also reported an increased number of
capillaries containing pericytes, which the authors interpreted as a pro-
tective scaffold to support the weak endothelium which showed junc-
tional leakiness. An interesting view proposed by Broadwell and
Salcman (1981) is that pericytes could also limit the damage of a
leaky BBB by acting as macrophages, degrading extravasated serum
proteins in their lysosomes.
Aliev and colleagues observed heterogeneous lesions in endothelial
cells of cerebral microvessels of AD brains (and transgenic mice overex-
pressing AβPP), which were absent in age-matched controls (Aliev
et al., 2002a, 2003, 2008; Aliyev et al., 2005). These vascular abnormal-
ities included clusters of mitochondria-derived lysosomes, large-sized
lipid vacuoles, and necrotic structures. Interestingly, in early AD sam-
ples without ultrastructural damage, the luminal side of endothelial
cells protruded into the vessel lumen, suggesting that the effects of hy-
poperfusion might precede ultrastructural damage (Aliyev et al., 2005).
Furthermore, the ultrastructural abnormalities of the vascular wall cells
co-localised with Aβ deposits around the microvessels (Aliev et al.,
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vealed the presence of atherosclerotic lesions and mtDNA deletions in
the damaged vascular wall, which were accompanied by increased
AβPP and oxidative stress markers (Aliyev et al., 2005). These vascular
abnormalities were associated with the selective damage to cortical
neurons (Aliyev et al., 2005; Aliev et al., 2008), suggesting that chronic
hypoperfusion might be a primary cause of the accumulation of oxida-
tive injury products (Aliev et al., 2009),whichwould initiate the process
of neurodegeneration. This hypothesis appears to be supported by the
notion that oxidative stress is an early event in AD pathogenesis (Aliev
et al., 2002a; Smith et al., 2000; Nunomura et al., 2001).
5. Network of causative relationships
Cerebral hypoperfusion and BBB dysfunction are key elements in the
vascular pathway to AD. In vitro findings supports the hypothesis that
factors resulting from cerebral hypoperfusion and BBB dysfunction are
also potential causing factors, suggesting the existence of detrimental
vicious circles.
The complex interconnections of endothelium-mediated mecha-
nisms reviewed in previous sections are synthesised here in the form
of a network of causative relationships linking the above mechanisms
(Fig. 1).
5.1. Chronic cerebral hypoperfusion
Ageing (the main risk factor for sporadic AD (De la Torre, 2002;
García-Escudero et al., 2013)), vascular conditions (Kelleher and Soiza,Fig. 1. Causative relationships of endothelium-mediated mechanisms of vascular dysfunction i
perfusion, and orange boxes indicate key mediators of vicious circles leading to hypoperfusio
pointing up inside a box indicate upregulation/increased quantity; arrows pointing down ind
Aβ: amyloid-β; AβPP: Aβ precursor protein; BACE-1: β-site AβPP cleaving enzyme 1; BBB: bloo
protein receptor-related protein 1; MEOX-2: mesenchyme homeobox gene-2; NO: nitric oxide
products; RNS: reactive nitrogen species; ROS: reactive oxygen species; TEER: transendothelia2013; Cordonnier and van der Flier, 2011; Zlokovic, 2011; Van Norden
et al., 2012; De la Torre, 2012), and possibly cardiac conditions (De La
Torre, 2004; Abete et al., 2014; Kalaria, 2003) cause chronic cerebral hy-
poperfusion. This in turn reduces oxygen and energy supply to the brain
tissue (Farkas et al., 2007), ultimately leading to neuronal damage.
Hypoperfusion also damages the BBB and is aggravated by vasogenic
oedema such as caused by pericyte detachment (Zlokovic, 2011) or vas-
cular cell death. Basal forebrain cholinergic deficit (a characteristic fea-
ture of AD (Farkas and Luiten, 2001; Van Beek and Claassen, 2011))
results in denervation of cortical microvessels (Hamel, 2004; Tong and
Hamel, 1999), further impairing CBF distribution. Hypoperfusion is
also aggravated by the ischemia-induced death of pericytes (Hall et al.,
2014), which constrict in rigour before dying, increasing resistance to
microvascular flow.
Indirect effects of chronic hypoperfusion such as oxidative stress, in-
flammation andmitochondrial dysfunction, cause BBB permeability and
structural damage to the microvascular wall (Aliev et al., 2002a). These
effects could mediate vicious circles, which could aggravate regional
CBF reduction (and reduction of oxygen/glucose supply to the brain),
ultimately accelerating the neurodegenerative process.5.2. Hypoxia/ischemia
Hypoxia induces BBB permeability (Yamagata et al., 2004;Mark and
Davis, 2002; Fischer et al., 1999, 2002; Engelhardt et al., 2014), ROS gen-
eration (Itoh et al., 2006; Strasser et al., 1997) and stimulates pro-
inflammatory gene expression (Tripathy et al., 2013; Sanchez et al.,
2012). Hypoxia and inflammation may cooperate in inducing BBBn AD pathogenesis. Green boxes indicate systemic factors causing regional cerebral hypo-
n aggravation. Arrows indicate causal relationship in the direction of the arrow. Arrows
icate the opposite. See text for further details. ABC: ATP binding cassette (transporter);
d–brain barrier; BF: basal forebrain; ER: endoplasmic reticulum; LRP-1: low-density lipo-
; PKC: protein kinase C; P-gp: P glycoprotein; RAGE: receptor for advanced glycation end-
l resistance; VEGF: vascular endothelial growth factor.
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BBB permeability induced by hypoxia (Abbruscato and Davis, 1999).
Hypoxia/ischemia affect AβPP processing and Aβ production (Peers
et al., 2009; Zhang et al., 2007; Bennett et al., 2000). Hypoxia also stim-
ulates endothelial angiogenic proteins, including VEGF (Grammas et al.,
2011b). However, the lack of vascular growth in response to VEGF
(Bürger et al., 2009) might cause a chronic state of endothelial activa-
tion, resulting in the release of proinflammatory and potentially neuro-
toxic products. Hypoxia is also associated with low levels of MEOX-2 in
AD, resulting in degradation of endothelial LRP-1, regression of capillary
networks, and reduced cerebral microcirculation (Sagare et al., 2012;
Wu et al., 2005). Reduced LRP-1 promotes perivascular accumulation
of Aβ. Because of the anti-angiogenic effect of Aβ (Grammas et al.,
1995b; Hayashi et al., 2009; Paris et al., 2004), there may be a coopera-
tive effect of hypoxia and Aβ to induce vascular regression and subse-
quent reduction of regional CBF, in a vicious circle.
Ischemia causes pericyte death and detachment (Hall et al., 2014).
The detachment of pericytes causes leakage of serum proteins and
focal microhaemorrhages (Zlokovic, 2011), resulting in vasogenic oede-
ma (Zlokovic, 2011), further contributing to hypoperfusion and hypoxia
of the surrounding parenchyma, thus aggravating neuronal injury.
Pericyte death in rigour causes a restriction of the capillary lumen
(Hall et al., 2014), with increased resistance to flow and consequent re-
duction of regional CBF.5.3. Oxidative stress
Excessive ROS and RNS production in oxidative stress causes
scavenging of NO (e.g., by sequestration into peroxynitrite), with sub-
sequent reduction of NO bioavailability (Zhu et al., 2007). Oxidative
stress also damages mitochondria (Harper et al., 2004; Aliev et al.,
2011). Because mitochondria are a major source of ROS and dys-
functional mitochondria can increase ROS production (Yao et al.,
2009), this might lead to a vicious circle which could aggravate BBB
damage.
Oxidative stress also decreases the expression of LRP-1 and
upregulates RAGE, potentially leading to increased perivascular Aβ de-
position (Cai et al., 2011). Furthermore, oxidative stress increases BBB
permeability, promotes leukocyte adhesion (Aliyev et al., 2005), and en-
dothelial release of the neurotoxic protease thrombin (Grammas et al.,
2004).5.4. Inflammation
Endothelial cells isolated from AD brains release inflammatory pro-
teins (Dorheim et al., 1994; Grammas and Ovase, 2001, 2002;
Frohman et al., 1991). Inflammation enhances the endothelial response
to hypoxia increasing BBB permeability. Astrocytes also contribute to
BBB permeability during inflammation by releasing inflammatory cyto-
kines (Abbott et al., 2006; Minagar et al., 2002).5.5. Mitochondrial dysfunction
Glucose and oxygen deprivation caused by chronic hypoperfusion
(Farkas et al., 2006), oxidative stress (Harper et al., 2004; Aliev et al.,
2011), and Aβ (Xu et al., 2001; Atamna and Frey, 2007; Suhara et al.,
2003; Crouch et al., 2005; Manczak et al., 2006; Caspersen et al., 2005;
Fossati et al., 2012) contribute to the dysregulation of mitochondrial
function. This in turn depletes ATP stores, impairs ATP-dependent trans-
port (of ions and Aβ), and increases intracellular Ca2+ concentration,
disrupting vital signalling pathways, and leading to apoptosis
(Zlokovic, 2011; De Bock et al., 2013). Dysfunctional mitochondria
also increase ROS production and oxidative damage in a vicious circle.5.6. Aβ–endothelium interaction
Aβ efflux transporters P-gp and LRP-1 decrease in AD (Van Assema
et al., 2012; Owen et al., 2010), suggesting a possible pathway to
perivascular Aβ accumulation. However, this contribution is likely mar-
ginal (Roberts et al., 2014).
Aβ dysregulates endothelial NO production (Gentile et al., 2004;
Toda and Okamura, 2012), possibly through the alteration of cytosolic
Ca2+ homeostasis (Gentile et al., 2004). Aβ-induced reduction of NO
bioavailability might also be mediated by oxidative stress (Park et al.,
2005). Inactivation of eNOS increases the expression of AβPP and
BACE-1, as well as Aβ production (Austin et al., 2010), potentially sus-
taining a vicious circle. Reduced endothelial NO production/bioavail-
ability in turn impairs regional CBF (De la Torre and Aliev, 2005).
Aβ–endothelium interaction induces BBB permeability (Deli et al.,
2010; Nishitsuji et al., 2011; Kook et al., 2012, 2013), possibly mediated
by PKC inactivation (Pakaski et al., 2002). Aβ also increases adherence
and transmigration of monocytes across the BBB (Giri et al., 2000,
2002; Gonzalez-Velasquez andMoss, 2008), mediated by the transcrip-
tion factor NF-kB (Gonzalez-Velasquez et al., 2011). Transmigrated
monocytes undergo differentiation into microglia (Eglitis and Mezey,
1997), and become activated in inflammatory conditions. The vasoac-
tive agents and cytokines released by activatedmicroglia can in turn in-
duce BBB permeability (Abbott et al., 2006; Luissint et al., 2012),
creating a paracellular route for mononuclear cell extravasation
(Abbott et al., 2010), in a vicious circle.
Furthermore, Aβ induces vasoconstrictor ET-1 release (Deane et al.,
2003; Palmer et al., 2013) – thus reducing regional CBF (Deane et al.,
2003) – and activates the endothelial inflammatory response
(Bamji-Mirza et al., 2014; Vukic et al., 2009). Finally, at high concentra-
tions Aβ causes endothelial apoptosis (Fonseca et al., 2013; Xu et al.,
2001; Blanc et al., 1997) by disrupting intracellular Ca2+ homeostasis.5.7. BBB permeability
BBB permeability is influenced by hypoxia/ischemia (Yamagata
et al., 2004; Mark and Davis, 2002; Fischer et al., 1999, 2002;
Engelhardt et al., 2014; Abbruscato and Davis, 1999), inflammation
(Abbott, 2000), oxidative stress (Cai et al., 2011), and Aβ (Deli et al.,
2010; Nishitsuji et al., 2011; Kook et al., 2012, 2013). Astrocytes also
contribute to BBB permeability during inflammation by releasing in-
flammatory cytokines (Abbott et al., 2006; Minagar et al., 2002), and
amplifying the endothelial response to ischemia by increasing junction-
al permeability (Chaitanya et al., 2014).
Alterations of the adrenergic microvascular innervation might alter
the (Na+/K+)-pump function of the BBB, possibly resulting in fluid bal-
ance impairment (Harik, 1986) and dysregulation of regional CBF.6. Conclusions
Based on the current literature on endothelium-mediated mecha-
nisms underlying vascular dysfunction in AD pathogenesis, this study
has presented a comprehensive overview of the complex network of
the interactingmechanisms,with particular emphasis on causative rela-
tionships, andmediators of detrimental vicious circles, such as hypoxia/
ischemia, oxidative stress, inflammation and mitochondrial dysfunc-
tion. The possible implication of other components of the BBB, such as
pericytes and astrocytes, in this complex scenario has also been
investigated.
As new mechanisms are discovered in this rapidly evolving field of
research, the proposed network can be expanded, adding new elements
(mechanisms) and/or interactions. Prospectively, this network could be
exploited in the identification of adequate therapeutic interventions to
treat, delay or prevent AD.
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